The definition of improvement changed the result
The trial randomized 1,248 adults with low defecation frequency and abdominal discomfort to one of two BB-12 amounts or placebo for four weeks. BB-12 is a named Bifidobacterium animalis subsp. lactis strain. [1]
The original frequency-responder comparison did not reach conventional statistical significance, and global discomfort relief did not differ. A stricter responder definition and average frequency analyses favored probiotic treatment. These results should be reported together. [1]
More frequent stools do not guarantee broad symptom relief
The two tested amounts produced similar frequency effects. That does not establish that a larger CFU count is always better or that the findings apply to every B. lactis strain. [1]
The participants were described as otherwise healthy adults with these complaints, not a universal sample of bowel disease. Chr. Hansen funded the study and its reporting; authors disclosed employment or consultancy relationships with the company. [1]
Keep both endpoints in the conclusion
Imagine stool frequency improves while overall discomfort does not. Calling the result a frequency improvement is more precise than saying every digestive symptom improved.
| Detail | Interpretation |
|---|---|
| Frequency analyses | Some favorable findings |
| Overall discomfort | No significant difference |
| Higher tested amount | No clear extra frequency effect |
Sources for this article
- Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial - PMC
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.